JP2019532927A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019532927A5 JP2019532927A5 JP2019514754A JP2019514754A JP2019532927A5 JP 2019532927 A5 JP2019532927 A5 JP 2019532927A5 JP 2019514754 A JP2019514754 A JP 2019514754A JP 2019514754 A JP2019514754 A JP 2019514754A JP 2019532927 A5 JP2019532927 A5 JP 2019532927A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- acetaminophen
- preparation
- contain
- ether cyclodextrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 32
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 28
- 239000000203 mixture Substances 0.000 claims 22
- 238000009472 formulation Methods 0.000 claims 20
- 229960005489 paracetamol Drugs 0.000 claims 16
- 229920000858 Cyclodextrin Polymers 0.000 claims 14
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 14
- 125000004964 sulfoalkyl group Chemical group 0.000 claims 13
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 239000000872 buffer Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 claims 1
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 claims 1
- CDAWCLOXVUBKRW-UHFFFAOYSA-N 2-aminophenol Chemical compound NC1=CC=CC=C1O CDAWCLOXVUBKRW-UHFFFAOYSA-N 0.000 claims 1
- ZPSJGADGUYYRKE-UHFFFAOYSA-N 2H-pyran-2-one Chemical class O=C1C=CC=CO1 ZPSJGADGUYYRKE-UHFFFAOYSA-N 0.000 claims 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 claims 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- 229930195722 L-methionine Natural products 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims 1
- 239000008351 acetate buffer Substances 0.000 claims 1
- 229960004308 acetylcysteine Drugs 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 239000003098 androgen Substances 0.000 claims 1
- 229940030486 androgens Drugs 0.000 claims 1
- 239000006172 buffering agent Substances 0.000 claims 1
- 150000001768 cations Chemical class 0.000 claims 1
- 229960001803 cetirizine Drugs 0.000 claims 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims 1
- 229960003009 clopidogrel Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 229960001305 cysteine hydrochloride Drugs 0.000 claims 1
- NWVNXDKZIQLBNM-UHFFFAOYSA-N diphenylmethylpiperazine Chemical compound C1CNCCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 NWVNXDKZIQLBNM-UHFFFAOYSA-N 0.000 claims 1
- 229930003935 flavonoid Natural products 0.000 claims 1
- 150000002215 flavonoids Chemical class 0.000 claims 1
- 235000017173 flavonoids Nutrition 0.000 claims 1
- 229940124307 fluoroquinolone Drugs 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000008176 lyophilized powder Substances 0.000 claims 1
- 229960004452 methionine Drugs 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000008363 phosphate buffer Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 229960001285 quercetin Drugs 0.000 claims 1
- 235000005875 quercetin Nutrition 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022125300A JP2022140780A (ja) | 2016-09-16 | 2022-08-05 | アセトアミノフェンおよびスルホアルキルエーテルシクロデキストリンを含む製剤 |
| JP2024028183A JP2024051102A (ja) | 2016-09-16 | 2024-02-28 | アセトアミノフェンおよびスルホアルキルエーテルシクロデキストリンを含む製剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662395794P | 2016-09-16 | 2016-09-16 | |
| US62/395,794 | 2016-09-16 | ||
| PCT/US2017/051919 WO2018053358A1 (en) | 2016-09-16 | 2017-09-15 | Formulations containing acetaminophen and sulfoalkyl ether cyclodextrin |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022125300A Division JP2022140780A (ja) | 2016-09-16 | 2022-08-05 | アセトアミノフェンおよびスルホアルキルエーテルシクロデキストリンを含む製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019532927A JP2019532927A (ja) | 2019-11-14 |
| JP2019532927A5 true JP2019532927A5 (enExample) | 2020-11-05 |
| JP7181185B2 JP7181185B2 (ja) | 2022-11-30 |
Family
ID=61619250
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019514754A Active JP7181185B2 (ja) | 2016-09-16 | 2017-09-15 | アセトアミノフェンおよびスルホアルキルエーテルシクロデキストリンを含む製剤 |
| JP2022125300A Pending JP2022140780A (ja) | 2016-09-16 | 2022-08-05 | アセトアミノフェンおよびスルホアルキルエーテルシクロデキストリンを含む製剤 |
| JP2024028183A Pending JP2024051102A (ja) | 2016-09-16 | 2024-02-28 | アセトアミノフェンおよびスルホアルキルエーテルシクロデキストリンを含む製剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022125300A Pending JP2022140780A (ja) | 2016-09-16 | 2022-08-05 | アセトアミノフェンおよびスルホアルキルエーテルシクロデキストリンを含む製剤 |
| JP2024028183A Pending JP2024051102A (ja) | 2016-09-16 | 2024-02-28 | アセトアミノフェンおよびスルホアルキルエーテルシクロデキストリンを含む製剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12527755B2 (enExample) |
| EP (1) | EP3512511A4 (enExample) |
| JP (3) | JP7181185B2 (enExample) |
| KR (2) | KR20240005122A (enExample) |
| CN (2) | CN116869983A (enExample) |
| AU (3) | AU2017326519B2 (enExample) |
| CA (1) | CA3036989A1 (enExample) |
| MX (2) | MX2019002976A (enExample) |
| WO (1) | WO2018053358A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119233815A (zh) * | 2022-05-20 | 2024-12-31 | 株式会社大赛璐 | 液态医药组合物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2751875B1 (fr) | 1996-08-05 | 1998-12-24 | Scr Newpharm | Nouvelles formulations liquides stables a base de paracetamol et leur mode de preparation |
| US6046177A (en) * | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
| RU2173172C2 (ru) | 1997-05-05 | 2001-09-10 | Сайдекс Инк. | Твердые фармацевтические препараты, содержащие физическую смесь сульфоалкилового эфира циклодекстрина и терапевтического агента |
| US7034013B2 (en) | 2001-03-20 | 2006-04-25 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
| US6869939B2 (en) | 2002-05-04 | 2005-03-22 | Cydex, Inc. | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
| EP2307056B1 (en) * | 2008-01-17 | 2021-12-15 | Pharmis Biofarmacêutica, LDA | Stabilized aqueous formulation containing paracetamol |
| DK2277546T3 (en) * | 2009-07-23 | 2015-08-17 | Uni Pharma Kleon Tsetis Pharmaceutical Lab S A | Stable, ready to use, injectable paracetamol formulation |
| SG10201507554RA (en) | 2010-09-13 | 2015-10-29 | Bev Rx Inc | Aqueous drug delivery system comprising off - flavor masking agent |
| EP2508558B1 (en) | 2011-04-07 | 2014-05-21 | Borealis AG | Silane crosslinkable polymer composition |
| US9493582B2 (en) * | 2012-02-28 | 2016-11-15 | Cydex Pharmaceuticals, Inc. | Alkylated cyclodextrin compositions and processes for preparing and using the same |
| CN102871994B (zh) | 2012-09-29 | 2015-07-29 | 中国科学院大连化学物理研究所 | 氟比洛芬对乙酰氨基酚酯环糊精包合物及其制备方法 |
| BR102014005885B1 (pt) * | 2014-03-13 | 2021-04-13 | Biotec Biológica Indústria Farmacêutica Ltda E.P.P | Formulação farmacêutica líquida injetável estável de paracetamol em bolsa plástica pronta para uso |
| DK3411047T3 (da) * | 2016-02-04 | 2021-06-28 | Czap Res And Development Llc | Kontrolleret udløsning og stratificeret cyclodextrin inklusionskompleks bæremedier |
-
2017
- 2017-09-15 JP JP2019514754A patent/JP7181185B2/ja active Active
- 2017-09-15 MX MX2019002976A patent/MX2019002976A/es unknown
- 2017-09-15 US US16/333,576 patent/US12527755B2/en active Active
- 2017-09-15 CA CA3036989A patent/CA3036989A1/en active Pending
- 2017-09-15 AU AU2017326519A patent/AU2017326519B2/en active Active
- 2017-09-15 KR KR1020237043884A patent/KR20240005122A/ko not_active Ceased
- 2017-09-15 EP EP17851668.8A patent/EP3512511A4/en active Pending
- 2017-09-15 CN CN202310814285.1A patent/CN116869983A/zh active Pending
- 2017-09-15 CN CN201780071033.7A patent/CN110167543A/zh active Pending
- 2017-09-15 WO PCT/US2017/051919 patent/WO2018053358A1/en not_active Ceased
- 2017-09-15 KR KR1020197010786A patent/KR20190065296A/ko not_active Ceased
-
2019
- 2019-03-14 MX MX2023003761A patent/MX2023003761A/es unknown
-
2022
- 2022-08-05 JP JP2022125300A patent/JP2022140780A/ja active Pending
-
2023
- 2023-06-13 AU AU2023203660A patent/AU2023203660A1/en not_active Abandoned
-
2024
- 2024-02-28 JP JP2024028183A patent/JP2024051102A/ja active Pending
-
2025
- 2025-06-06 AU AU2025204233A patent/AU2025204233A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6824434B2 (ja) | ネココロナウイルス感染を処置する方法 | |
| JP2018021007A5 (enExample) | ||
| JP2020007356A5 (enExample) | ||
| JOP20220069A1 (ar) | عوامل محللة لـ brd9 ثنائية الوظيفة وطرق لاستخدامها | |
| JP2013513612A5 (enExample) | ||
| JP2016534142A5 (enExample) | ||
| JP2016534063A5 (enExample) | ||
| RU2668882C2 (ru) | Жидкая фармацевтическая композиция | |
| JP2004512328A5 (enExample) | ||
| JP6094388B2 (ja) | ペメトレキセドを含む注射用組成物 | |
| JP2015521617A5 (enExample) | ||
| HRP20230929T1 (hr) | Stabilni pripravci semaglutida i njihova upotreba | |
| ES2685469T3 (es) | Suspensión y composición de torta que contienen derivado de carboestirilo y aceite de silicona y/o derivado de aceite de silicona | |
| US20220339141A1 (en) | Combination treatment with a p53 reactivator and an inhibitor of an antiapoptotic bcl-2 family protein | |
| JP2016516773A5 (enExample) | ||
| PH12017502252A1 (en) | Stable pharmaceutical composition for oral administration | |
| JP2017534652A5 (enExample) | ||
| UA77736C2 (en) | Pharmaceutical composition based on azetidine derivatives | |
| JP2019532927A5 (enExample) | ||
| JP2014534215A5 (enExample) | ||
| JP2017516828A5 (enExample) | ||
| JP2015534985A5 (enExample) | ||
| WO2011064663A1 (en) | Combination treatment employing belinostat and bicalutamide | |
| JP2018504391A5 (enExample) | ||
| JP2020518608A5 (enExample) |